ASCO GI: mTOR Inhibitor Slows Advanced pNET (CME/CE)

SAN FRANCISCO (MedPage Today) — Patients with advanced pancreatic neuroendocrine tumors (pNET) had more than a twofold increase in progression-free survival when treated with a mammalian target of rapamycin (mTOR) inhibitor, investigators reported.

Post a Comment

Comments are closed.